> top > docs > PubMed:12150730 > annotations

PubMed:12150730 JSONTXT

Annnotations TAB JSON ListView MergeView

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 195-203 HP_0002861 denotes melanoma
T2 236-241 HP_0002664 denotes tumor
T3 259-283 HP_0001402 denotes hepatocellular carcinoma

DisGeNET

Id Subject Object Predicate Lexical cue
T0 195-211 gene:51152 denotes melanoma antigen
T1 259-283 disease:C2239176 denotes hepatocellular carcinoma
T2 195-211 gene:51152 denotes melanoma antigen
T3 285-288 disease:C2239176 denotes HCC
T4 215-221 gene:4100 denotes MAGE-1
T5 259-283 disease:C2239176 denotes hepatocellular carcinoma
T6 215-221 gene:728239 denotes MAGE-1
T7 259-283 disease:C2239176 denotes hepatocellular carcinoma
T8 215-221 gene:81557 denotes MAGE-1
T9 259-283 disease:C2239176 denotes hepatocellular carcinoma
T10 215-221 gene:4100 denotes MAGE-1
T11 285-288 disease:C2239176 denotes HCC
T12 215-221 gene:728239 denotes MAGE-1
T13 285-288 disease:C2239176 denotes HCC
T14 215-221 gene:81557 denotes MAGE-1
T15 285-288 disease:C2239176 denotes HCC
R1 T0 T1 associated_with melanoma antigen,hepatocellular carcinoma
R2 T2 T3 associated_with melanoma antigen,HCC
R3 T4 T5 associated_with MAGE-1,hepatocellular carcinoma
R4 T6 T7 associated_with MAGE-1,hepatocellular carcinoma
R5 T8 T9 associated_with MAGE-1,hepatocellular carcinoma
R6 T10 T11 associated_with MAGE-1,HCC
R7 T12 T13 associated_with MAGE-1,HCC
R8 T14 T15 associated_with MAGE-1,HCC

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 155-290 OBJECTIVE denotes To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma (HCC).
T2 300-1095 METHODS denotes The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I(HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 peptide (NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.
T3 1105-2416 RESULTS denotes The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10:1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3.3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.
T4 2429-2768 CONCLUSIONS denotes The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.